However, novel treatments developed in the future, with further study of the PNPLA3 p.I148M variant, will hopefully alleviate a significant genetic risk factor of NAFLD and contribute to the advancement of personalised therapies. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.